Igraine (AQSE:KING) Current Deferred Revenue : £0.00 Mil (As of . 20)

View and export this data going back to 2008. Start your Free Trial

What is Igraine Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Igraine's current deferred revenue for the quarter that ended in . 20 was £0.00 Mil.

Igraine Current Deferred Revenue Historical Data

The historical data trend for Igraine's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Igraine Current Deferred Revenue Chart

Igraine Annual Data

Trend

Current Deferred Revenue

Igraine Semi-Annual Data

Current Deferred Revenue

Igraine Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Igraine's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Igraine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Igraine PLC (AQSE:KING) » Definitions » Current Deferred Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 Primrose Street, 8th Floor, The Broadgate Tower, London, GBR, EC2A 2EW

Website

https://www.igraineplc.com

Igraine PLC is an investment company. Its business investment is to source and develops breakthrough technologies and commercially attractive discoveries in the health, Medtech, Biotech, and life science sectors.